NCT06111846View on ClinicalTrials.gov

Study of Human Bone Marrow Mesenchymal Stem Cells in APAP

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

July 22, 2025

Study Completion Date

August 30, 2026

Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
DRUG

human Bone Marrow Mesenchymal Stem Cell (hBMMSC)

Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)

Trial Locations (1)

100021

JiuzhitangMakerBeijingCellTech, Beijing

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.

OTHER

NCT06111846 - Study of Human Bone Marrow Mesenchymal Stem Cells in APAP | Biotech Hunter | Biotech Hunter